Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.40B
Last updated: Nov 17, 2026 at 4:40 PM ET
Royalty Pharma Plc (RPRX) Statistics
Royalty Pharma Plc (RPRX) has a market cap of $39.40B and an enterprise value of $47.48B. It kept 44.80% of revenue as net income over the last 12 months. Its trailing P/E of 13.0x is above its 5-year median of 8.2x.
Total Valuation
Enterprise value is 20.49% above the market cap, as debt exceeds cash.
| Market Cap | $39.40B |
|---|---|
| Enterprise Value | $47.48B |
| Latest price (Nov 17, 2026) | $68.68 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 13, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Last Ex-Dividend Date | Nov 13, 2026 |
| Next Payment Date | Dec 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.7x and 4.5x. Its year-end P/E ranged from 5.9x to 13.7x from 2020 to 2025.
| P/E Ratio | 13.0x |
|---|---|
| Forward P/E | 12.6x |
| P/S Ratio | 11.7x |
| Forward P/S | 11.2x |
| P/B Ratio | 4.5x |
| P/TBV Ratio | 5.2x |
| P/OCF Ratio | 13.3x |
| PEG Ratio | 1.2 |
Enterprise Valuation
Counting debt and cash, the company is valued at 26.1x EBITDA.
| EV / Earnings | 40.5x |
|---|---|
| EV / Sales | 18.1x |
| EV / EBITDA | 26.1x |
| EV / EBIT | 32.0x |
Price Statistics
The stock is up 77.08% over 52 weeks and trades 11.55% above its 50-day average.
| Beta (1Y) | 0.24 |
|---|---|
| 52-Week Change | +77.08% |
| 1-Month Change | +14.34% |
| 3-Month Change | +11.64% |
| 6-Month Change | +31.57% |
| 5-Year Change | +69.95% |
| Total Return (1Y) | +79.50% |
| Total Return (3Y CAGR) | +40.16% |
| Total Return (5Y CAGR) | +12.77% |
| Return vs SPY (1Y) | +64.17% |
| Max Drawdown (1Y) | -12.12% |
| Max Drawdown (3Y) | -20.67% |
| Sharpe Ratio (1Y) | 2.57 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $61.57 |
| 200-Day Average | $54.60 |
| 52-Week Range | $36.68 to $70.13 |
| RSI (14 Days) | 67.8 |
| Average Volume (20 Days) | 3.43M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.29x current liabilities, and total debt is 1.26x shareholder equity.
| Current Ratio | 1.29x |
|---|---|
| Quick Ratio | 1.29x |
| Debt / Equity | 1.26x |
| Debt / EBITDA | 5.80x |
| Interest Coverage | 3.98x |
Returns and Efficiency
Return on invested capital is 7.59% over the last 12 months, against a 5-year average of 7.56%.
| Return on Equity (ROE) | 17.15% |
|---|---|
| Return on Assets (ROA) | 6.02% |
| Return on Invested Capital (ROIC) | 7.59% |
| Return on Capital Employed (ROCE) | 8.10% |
| ROE (5Y Average) | 18.25% |
| ROA (5Y Average) | 6.58% |
| ROIC (5Y Average) | 7.56% |
| Asset Turnover | 0.13x |
Taxes
Income tax took 0.00% of pretax income over the last 12 months.
| Income Tax (TTM) | $0 |
|---|---|
| Effective Tax Rate | 0.00% |
Scores
RPRX has an Altman Z-Score of 2.49, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.49 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.62B over the last 12 months is up 11.36% from the 12 months before.
| Revenue | $2.62B |
|---|---|
| Revenue Growth (YoY) | +11.36% |
| Gross Profit | $2.62B |
| Operating Income | $1.50B |
| Pretax Income | $1.17B |
| Net Income | $1.17B |
| EBIT | $1.48B |
| Reported EPS (TTM) | $5.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 35.15% of the $19.46B in total assets.
| Cash and Equivalents | $513.66M |
|---|---|
| Total Debt | $8.59B |
| Net Debt | $8.07B |
| Net Debt Per Share | $18.10 |
| Working Capital | $346.56M |
| Shareholder Equity | $6.84B |
| Book Value Per Share | $15.33 |
| Tangible Book Value | $5.91B |
| Tangible Book Per Share | $13.26 |
| Total Assets | $19.46B |
| Total Liabilities | $9.67B |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $2.96B |
|---|---|
| FCF Per Share | $6.65 |
| Dividends Paid | $893.47M |
| Share Repurchases | $261.62M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 57.14%, against a 5-year average of 52.45%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 57.14% |
| Pretax Margin | 44.80% |
| Net Margin | 44.80% |
| EBIT Margin | 56.61% |
| Operating Margin (5Y Average) | 52.45% |
| Net Margin (5Y Average) | 50.23% |
Growth
Revenue grew 2.06% a year over 3 years, and EPS 9.56% a year.
| Revenue Growth (3Y CAGR) | +2.06% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.30% |
| EPS Growth (3Y CAGR) | +9.56% |
| EPS Growth (5Y CAGR) | -2.70% |
| FCF Growth (3Y CAGR) | +189.30% |
| Operating Income Growth (3Y CAGR) | +71.89% |
| Book Value Per Share Growth (2Y CAGR) | +3.33% |
| Tangible Book Per Share Growth (2Y CAGR) | -4.33% |
Dividends and Yields
RPRX pays out 35.76% of earnings as dividends.
| Dividend Per Share (Annual) | $0.94 |
|---|---|
| Dividend Yield | 1.37% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +5.01% |
| Payout Ratio | 35.76% |
| Earnings Yield | 7.69% |
| Buyback Yield | 0.85% |
| Shareholder Yield | 3.77% |
Peer Position
Against 6 similar companies, RPRX has the lowest P/E.
P/E RatioPeer median 31.5x
P/S RatioPeer median 16.7x
ROICPeer median 4.15%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +18.59%
Dividend YieldPeer median 0.00%
| P/E Ratio | 13.0x vs 31.5x median |
|---|---|
| P/S Ratio | 11.7x vs 16.7x median |
| ROIC | 7.59% vs 4.15% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.36% vs +18.59% median |
| Dividend Yield | 1.37% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 27.62% and EPS growth at 10.51% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +27.62% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +10.51% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RPRX
What is RPRX's market cap?
Royalty Pharma Plc has a market cap of $39.40B. Its enterprise value, which adds debt and subtracts cash, is $47.48B.
What is RPRX's P/E ratio?
Royalty Pharma Plc has a trailing P/E ratio of 13.0x and a forward P/E of 12.6x.
How many shares of RPRX are outstanding?
Royalty Pharma Plc has 446.03M shares outstanding. The count is up 3.28% from a year earlier.
Does RPRX pay a dividend?
Yes. Royalty Pharma Plc pays $0.94 a share a year, a dividend yield of 1.37%.
How much debt does RPRX have?
Royalty Pharma Plc has $8.59B of total debt and $513.66M of cash and equivalents, a net debt position of $8.07B.
RPRX pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors